Artgen Biotech (MOEX: ABIO) is in the GR rating of the 200 largest Russian companies without government participation 2023, reaffirming its high level of corporate GR (Government Relations). The rating was developed by GRT Consulting in 2022 and has been conducted annually since then. Participation in the rating is voluntary and free of charge, and the results are published on the company’s website.
All companies selected for the 2023 GR rating are major market players in their industry segments and fall within the scope of state interests, demonstrating a sufficient level of transparency in their GR function.
The main goal of the rating is to promote technologies and tools for interaction between business and government authorities. Participation in the rating allows companies to assess the current state of their GR function and identify areas for improvement.
The rating is based on a methodology for auditing the GR function of commercial organizations without state participation among their founders which GRT Consulting has developed and tested over the past 5 years while working on consulting projects. Companies’ positions in the rating are determined using the GRTindex™, which is calculated based on responses to an online questionnaire available on the company’s website.
GRT Consulting was founded in 2017 and provides services in the field of corporate GR and strategic development of organizations.